Search


Jefferies London 2026: Nektar Therapeutics has Rezpeg moving full speed ahead in atopic dermatitis and alopecia (and beyond) - the Head of R&D shares learnings about its mechanism
Jonathan Zalevsky describes how learnings from the phase 2 AD trial have helped with the study design of three phase 3 studies - and the latest on alopecia. He emphasizes how the company seems to be seeing a deepening of responses from this Treg targeting mechanism over time. Coverage brought to you by
3 hours ago


Physican and Biotech Investor Adam May reacts to this morning's 52 week Rezpeg data in alopecia from Nektar
He shares his thoughts on the data, the competitive profile of this IL-2 Treg therapy vs JAK inhibitors, and how the overall platform looks for other I&I conditions.
Apr 20






.png)
